Skip to content

O G Berge

2 papers in the library · 54 citations · publishing 1980-1983

Papers

Nociception is enhanced after low doses and reduced after high doses of the serotonin receptor agonist 5-methoxy-N,N-dimethyltryptamine.

Neuroscience letters September 1, 1980 O G Berge, K Hole, H Dahle 34 citations

Injecting 5-methoxy-N,N-dimethyltryptamine into the brain's ventricles altered pain sensitivity in rats, measured by the tail-flick test. Low doses (1.6 to 25 micrograms) reduced tail-flick latencies by 13-24%, indicating hyperalgesia (increased pain sensitivity), likely from decreased activity in descending serotonergic neurons. Moderate doses (50 and 100 micrograms) produced a biphasic response: initial hyperalgesia followed by analgesia. The highest dose (400 micrograms) increased latencies by 28-39%, indicating analgesia, probably by stimulating spinal postsynaptic serotonergic receptors.

Inhibitory effect of 5-methoxy-N,N-dimethyltryptamine on the synaptosomal uptake of 5-hydroxytryptamine.

European journal of pharmacology June 3, 1983 O G Berge, D Chacho, K Hole 20 citations

5-MeO-DMT, a psychedelic compound, inhibits the reuptake of serotonin in rat brain tissue at concentrations between 0.5 and 500 micromolar, affecting the striatum, hippocampus, and hypothalamus. At higher concentrations (10 micromolar), it also inhibits dopamine reuptake and triggers the release of both serotonin and dopamine from nerve endings. These findings suggest that 5-MeO-DMT's effects as a serotonin agonist may involve blocking reuptake, not just directly stimulating receptors as previously thought.